We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Senesco Technologies reported that mice treated with Senesco's proprietary technology
have shown a marked survival benefit in the lethal sepsis study conducted at
the University of Virginia by W. Michael Scheld.
Cortex Pharmaceuticals announced that preliminary analysis suggests that CX717,
when compared to placebo, increased wakefulness in a dose-related manner and
improved performance in healthy male subjects that became impaired during 27
hours without sleep.
Bentley Pharmaceuticals has announced that one of its Spanish subsidiaries,
Laboratorios Davur, has received approval to market 1-, 3- and 6-mg generic
dosage versions of risperidone in Spain.
Avanir Pharmaceuticals has announced the signing of a global research, development
and commercialization agreement with Novartis to develop orally active small
molecule therapeutics targeting macrophage migration inhibitory factor (MIF)
as potential treatments for inflammatory diseases.